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Background: Tacaribe virus (TCRV) is a less biohazardous relative of the highly pathogenic clade B New World
arenaviruses that cause viral hemorrhagic fever syndromes and require handling in maximum containment facilities
not readily available to most researchers. AG129 type I and II interferon receptor knockout mice have been shown
to be susceptible to TCRV infection, but the pathogenic mechanisms contributing to the lethal disease are unclear.
Methods: To gain insights into the pathogenesis of TCRV infection in AG129 mice, we assessed hematologic and
cytokine responses during the course of infection, as well as changes in the permeability of the vascular endothelium.
We also treated TCRV-challenged mice with MY-24, a compound that prevents mortality without affecting viral loads
during the acute infection, and measured serum and tissue viral titers out to 40 days post-infection to determine
whether the virus is ultimately cleared in recovering mice.
Results: We found that the development of viremia and splenomegaly precedes an elevation in white blood cells and
the detection of high levels of proinflammatory mediators known to destabilize the endothelial barrier, which likely
contributes to the increased vascular permeability and weight loss that was observed several days prior to when the
mice generally succumb to TCRV challenge. In surviving mice treated with MY-24, viremia and liver virus titers were not
cleared until 2–3 weeks post-infection, after which the mice began to recover lost weight. Remarkably, substantial viral
loads were still present in the lung, spleen, brain and kidney tissues at the conclusion of the study.
Conclusions: Our findings suggest that vascular leak may be a contributing factor in the demise of TCRV-infected
mice, as histopathologic findings are generally mild to moderate in nature, and as evidenced with MY-24 treatment,
animals can survive in the face of high viral loads.
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An expanding group of close to 30 viruses comprise the
Arenaviridae family of viruses. Novel arenaviruses are
being discovered, on average, every 2–3 years, and the
recent emergence of novel pathogenic arenavirus species
suggests that others will be identified in the near future
[1,2]. Arenaviruses cause asymptomatic chronic infections
in their respective rodent reservoir hosts and are primarily* Correspondence: brian.gowen@usu.edu
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reproduction in any medium, provided the ortransmitted to humans through inhalation of aerosolized
infectious excreta or secretions. Human disease varies
widely from asymptomatic or mild febrile illnesses that
clear within a few days to severe life-threatening hemor-
rhagic fever (HF) requiring prompt medical attention. The
onset of arenaviral HF generally proceeds inconspicuously
with immunosuppression, high viremia, hypercytokinemia,
increased vascular permeability, reduced perfusion and
eventually hypovolemic shock [3]. There are presently 7
arenaviruses known to cause viral HF. The group includes
5 New World viruses (Junin, Machupo, Guanarito, Sabia,
and Chapare) present in areas of South America, and twoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regions of Western and South Africa [4,5].
The New World arenaviruses (NWA) are comprised of
3 distinct clades (A, B and C) within the Tacaribe complex
[6]. Clade B contains the 5 pathogenic arenavirues and
several closely related non-pathogenic viruses including
Tacaribe virus (TCRV), first isolated in 1956 from a fruit-
eating bat (Artibeuslituratus) on the island of Trinidad [7].
TCRV is most closely related phylogenetically to Junin
virus (JUNV) [4], the etiologic agent of Argentine HF.
JUNV has produced the greatest disease burden due to
infection by the pathogenic NWA, with case fatality
rates ranging from 15-30% in hospitalized patients [8].
Dysregulation of the host innate immune response by
JUNV and other pathogenic NWA is believed to impair
the development of protective immunity, leading to
morbidity and, in many cases, death [3,9].
In addition to public health concerns due to natural
transmission of pathogenic NWA in endemic regions of
South America, these viruses are considered bioterror
agents that could be intentionally released [10]. The lack
of safe and effective FDA-approved therapeutic options
to treat severe arenavirus infections and the aerosol
transmissibility of the viruses contribute to the designa-
tion of JUNV and other HF-causing NWA as highest
priority category A NIAID pathogens [11], and under-
scores the need to develop new treatment strategies to
counter arenavirus infections. Until recently, mouse models
suitable for early stage antiviral drug development had
not been described [5]. Lethal JUNV and Machupo virus
(MACV) challenge models based on infection of mice
deficient in α/β and γ interferon (IFN) receptors [12] or
the STAT1 IFN signaling component [13] now provide
systems in which promising compounds can be evalu-
ated. However, such studies are generally cost prohibi-
tive due to the requirement of biosafety level (BSL) 4
maximum containment facilities that are not readily
accessible to most researchers.
A third mouse model for proof-of-concept antiviral
drug studies has also been developed using TCRV, a less
biohazardous clade B arenavirus than can be worked
with safely in BSL2 laboratories and animal facilities. In
addition to describing basic natural history data on the
development of viral titers and histopathology during
infection, the model was also used to evaluate MY-24, a
small molecule that was found to have moderate anti-
viral activity in vitro against TCRV and the Candid vaccine
strain of JUNV [14]. Remarkably, the compound was highly
effective in preventing mortality in TCRV-challenged mice
without reducing viral loads, suggesting that host factors
may contribute substantially to the disease pathogenesis. In
the present study, we characterize the host response to
TCRV infection in the AG129 mouse model and include
associated viral titer and histopathology findings to allowdirect correlation of the data. We also report on the clear-
ance of virus in surviving mice treated with MY-24, which
was not addressed previously.
Results
AG129 mice were challenged with a lethal dose of TCRV
and groups of animals were sacrificed daily for collection
of blood and tissue samples for a comprehensive temporal
analysis of the host response during the acute infection.
As seen in Figure 1, TCRV was present in the serum and
all tissues examined. Virus first became apparent in the
circulation on day 6 in 2 of 4 challenged mice, and titers
gradually increased until reaching mean levels above 7.25
log10 50% cell culture infectious doses (CCID50)/ml on day
9 (Figure 1A). Liver virus was detected in one animal as
early as day 6, with peak titers rising to 7.75 log10 CCID50/
g by day 9 (Figure 1B). By gross visual examination, liver
samples taken from day 10 mice were a pale mahogany
color in 2 of the 4 survivors. Substantial lung virus titers
could be detected in 75% of the mice on day 7, with in-
creasing burden thereafter, reaching peak levels (approxi-
mately 6.75 log10 CCID50/g) on day 10 (Figure 1C). Gross
examination of lungs revealed necrotic lesions on day 9
and thereafter. The first organ to present with signifi-
cant amounts of TCRV replication was the spleen, with
>4.75 log10 CCID50/g on day 5 of the infection, and
sustained virus burden of >6.5 log10 CCID50/g out to
day 10 (Figure 1D). In several spleen samples collected
on and after day 8, gross examination revealed spleno-
megaly with pale red coloration. TCRV was found in the
brain in 1 of 4 animals on day 8 and all infected animals
thereafter, with up to 6 log10 CCID50/g present on days
9 and 10 (Figure 1E). Substantial kidney virus was not
observed until day 8 of infection, with the highest mean
viral loads of >6.5 log10 CCID50/g seen on days 9 and 10
(Figure 1F).
In addition to the virologic anlaysis, the weights of the
mice were measured every other day to limit handling
stress. The mean weight of the TCRV-infected mice dropped
sharply from day 6 to day 8, with the trend continuing
to day 10, the final day of measurement (Figure 2A).
The weight loss was consistent with the development of
viremia(Figure 1A) and the onset of lethargy and ruf-
fling of fur on day 8 post-infection. Also consistent with
the viral titer data, splenomegaly observed in the visual
examination was confirmed starting on day 6, with spleens
doubling in weight on days 7 and 8 compared to those
from the sham-infected controls (Figure 2B).
Histologic examination of livers collected on day 8 and
later showed multifocal random hepatocellular necrosis
and granulomatous inflammation characterized by infiltra-
tion of macrophages, fewer neutrophils and lymphocytes
in the hepatic parenchyma (Figure 3A). Lymphocytes,




Figure 1 Temporal analysis of serum and tissue virus titers in AG129 mice challenged with TCRV. Groups of 4 animals were sacrificed on
the specified days of infection for analysis of A) serum, B) liver, C) lung, D) spleen, E) brain, and F) kidney virus titers. One of 5 mice in the day-10
group succumbed prior to the time of sacrifice.
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plate. Glycogen stores in hepatocytes were depleted.
Histologic analysis of lungs revealed interstitial pneu-
monia on day 8 and thereafter (Figure 3C). Examination
of spleens on day 8–10 post-infection revealed a moderate
to marked increased area and cellularity of the marginal
zones due to increased number of atypical mononuclear
cells (Figure 3E). There was also a moderate decrease of
lymphocyte area and cellularity of the periarteriolar
lymphoid sheath and lymphoid follicle as well as de-
creased red pulp area and cellularity.
Hematologic analysis showed a precipitous increase in
white blood cell (WBC) counts starting on day 8, as was
also the case for granulocyte and lymphocyte popula-
tions (Figure 4A-C). Notably, platelet counts did not de-
crease in the TCRV-infected animals (Figure 4D), which
is a characteristic feature of South American HF [15]. No
other significant changes were seen in the hematologic
analysis.
Cytokine levels in the mice were also examined from
days 5–10 in serum, brain and lung, days 4–10 for kidney,
days 3–10 for spleen, and days 3–9 for liver. As shown in
Table 1, serum concentrations of a number of cytokines
were dramatically increased as the TCRV infection
progressed. Proinflammatory mediators such as IL-6,
TNF-α, and MCP-1 increased over time during the course
of infection. Elevated systemic levels of these and other
cytokines have been associated with severe disease in
cases of viral hemorrhagic fever [15]. Notably, the lungs
had the greatest number of cytokines that were significantly
increased or demonstrated a trend towards higher levels
as the infection progressed (Table 1). Many of these cyto-
kines were also elevated in liver and spleen tissues. In thebrain and kidney, there was very little evidence of an in-
flammatory response to TCRV. There was a slight trend
suggesting increased levels of IL-6, with a more pro-
nounced elevation in MCP-1 in brain samples (Table 1).
No significant changes or trends suggesting increased
production of cytokines in response to TCRV infection
were observed in kidney tissue (data not shown). Col-
lectively, the cytokine profiling data supports a strong
proinflammatory response during the evolution of dis-
ease in response to TCRV infection in AG129 mice.
Because it was not possible to measure vascular perme-
ability as part of the initial host response characterization
experiment, we conducted a separate time course analysis
to track the movement of intravenously injected Evans
blue dye (EBD) into various primary tissues in TCRV-
challenged mice. As commonly seen, the mice chal-
lenged with TCRV exhibited clear signs of clinical illness
including lethargy and ruffling of fur by days 8 and 9
post-infection, and the deteriorating condition of the
animals was reflected in loss of body weight (Figure 5A).
By day 10, the infected mice were approaching a mori-
bund state and the animals that were the most morbid did
not show markedly blue extremities following EBD infu-
sion as seen in the sham-infected normal controls (not
shown).This is consistent with previously observed lack
of perfusion in a model of acute arenavirus infection in
hamsters, likely due to hypotension associated with vas-
cular leak [16].
When measuring systemic EBD levels, serum concen-
trations were reduced in the TCRV-infected control ani-
mals on days 8, 9 and 10 post-infection, suggesting leakage
of the dye into the viscera (Figure 5B). However, we cannot
rule out the possibility that the lower systemic EBD levels
BA
Figure 2 Whole body weight change and spleen weight in
AG129 mice during the course of TCRV infection. A) Body
weight data are represented as the group mean and standard
deviation of the percent change in weight of surviving animals
relative to their starting weights, measured at 2-day intervals.
B) Spleen weight data represent the mean and standard deviation
from groups of 4 TCRV-infected mice sacrificed at the indicated
times. Data from 1 sham-infected control animal per day are
included for comparison. n=40, 36, 28, 20, 12, and 4 for the
TCRV-infected mice, and n=10, 9, 7, 5, 3, and 1 mouse for the
normal controls, on day 0, 2, 4, 6, 8, and 10, respectively. *P< 0.05,
**P< 0.01, ****P< 0.001 compared to sham-infected animals.
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mice may be due to lack of absorption from the orbital
capillary nexus. Therefore, to more accurately access
vascular leak of EBD, the tissue concentrations were
normalized to amount of dye present in the serum. Liver,
kidney, lung and spleen showed a markedly higher mean
tissue to serum ratio in the TCRV-infected animals
compared to the sham-infected mice on days 8, 9 and
10 (Figure 5C-F), indicating that vascular leakage is oc-
curring and may be an important factor in the demise of
the AG129 mice challenged with TCRV.
Prophylactic MY-24 treatment during the first week of
TCRV infection has previously been shown to protectmice from mortality in the absence of an appreciable re-
duction in viral titers, suggesting that components of the
host response play a significant role in the pathogenesis
of the infection [14]. In the present study, we assessed
systemic and tissue viral loads out beyond 5 weeks in
surviving animals treated with MY-24 during days 3–10
of the acute infection. Confirming previous observations,
MY-24 did not significantly reduce day 8 viral titers in
the serum or any tissue compared to mice receiving
placebo (Figure 6). Only 3 of the 5 MY-24-treated mice
had detectable virus loads in the serum at day 8 post-
infection, with all surviving mice having viremia on day
16 (Figure 6A); however, virus was no longer detectable
at 24 days post-infection. In the liver, peak viral loads
of approximately 7.5 log10 CCID50/g of tissue were ob-
served on day 16 in the MY-24-treated mice, with virus
detected in only 2 of 4 animals on day 24, and absent in
all surviving mice at day 32 post-infection (Figure 6B).
In the lung, approximately 7 log10 CCID50/g was detected
on day 16, with a gradual decline in titers out to day 40
(Figure 6C). Remarkably, >5 log10 CCID50/g of lung virus
burden was still present at the end of the 40-day study.
The spleen was the only tissue in which the viral titers
trended higher in the MY-24-treated animals on day 8
post-infection (Figure 6D). Notably, 3 of the 5 MY-24-
treated mice had ≥9.5 log10 CCID50/g. Spleen viral burden
slightly decreased on days 16–40, but persisted similar
to that observed in the lung. On day 8 of the infection,
virus was found only in brain tissue from a single placebo-
treated animal (Figure 6E). However, substantial titers
were observed starting on day 16 ranging from 6 to 7.5
log10 CCID50/g of brain in surviving MY-24-treated
mice. TCRV persistence was also observed in the kidneys
of recovering MY-24-treated mice (Figure 6F). As in most
tissues, peak titers were observed on day 16 (approxi-
mately 6.5 log10 CCID50/g of kidney), with a subsequent
slight reduction in titer as the experiment progressed.
In general, MY-24-treated mice began to lose weight
after day 12 post-infection and started to recover the
lost weight starting on day 21 (Figure 7). These data are
consistent with peak titers being observed primarily on
day 16, with reductions in virus burden, in most cases,
by day 24 of the infection (Figure 6).
In addition to assessing the viral titers out to 40 days
post-infection, we also analyzed neutralizing anti-TCRV
titers. At 8 days post-infection, the results suggest that
low levels of neutralizing antibodies were elicited earlier
in placebo-treated animals (Figure 8). By day 16, PRNT50
titers were at their peak in the MY-24-treated mice and
waned thereafter. Compared to the PRNT50 titers from
immune serum from mice that were boosted with live
TCRV after having survived infection with a non-lethal
challenge dose, the primary neutralizing antibody re-





Figure 3 Histopathology in TCRV-infected AG129 mice at 9 days post-infection. Representative photomicrographs of liver A), lung C), and
spleen (E) from AG129 mice sacrificed on day 9 post-infection with TCRV. Liver B), lung D), and spleen F) from control sham-infected mice.
Hematoxylin and eosin staining shows A) multifocal moderate histiocytic, neutrophilic and lymphocytic hepatitis (400X), C) diffuse moderate
interstitial pneumonia (400X), and E) white pulp hyperplasia (200X). For panels A-D, bar = 50 μm; for E and F, bar = 100 μm.
Sefing et al. Virology Journal 2013, 10:221 Page 5 of 13
http://www.virologyj.com/content/10/1/221mice beyond day 16 (Figure 8). Nevertheless, on day 40,
all tissues were histologically normal (data not shown),
consistent with the healthy appearance of the mice re-
covering from the infection.
In a separate experiment, we also assessed vascular
permeability in selected tissues from treated mice to as-
sess the impact of MY-24at 9 days post-infection. EBD
content in the serum and tissues did not differ signifi-
cantly between the MY-24- and placebo-treated animals;
however, tissue EDB ratios were generally slightly lower in
mice treated with MY-24compared to placebo (Additional
file 1: Figure S1). Nevertheless, large numbers of mice
would have been required to statistically distinguish the
subtle, if any, effect that MY-24 may have on limiting
vascular leak.Discussion
The current paradigm in the viral HF field is that exag-
gerated release of proinflammatory cytokines into the
circulation is an important factor driving the devastating
vascular leakage that leads to systemic shock, multi-
organ failure, and death [15,17]. Therefore, the treat-
ment of advanced cases of viral HF would likely require
a combination of an effective antiviral that directly dis-
rupts the virus life cycle with an agent that can limit the
collateral damage caused by an overly aggressive host re-
sponse. Our data measuring vascular integrity in mice
during the acute phase of TCRV infection indicates that
vascular leak is a part of the disease process, but its
overall contribution to the decline of the animals is diffi-









Figure 4 Hematologic response to TCRV infection in AG129 mice. Whole blood samples collected from the temporal analysis study were
analysed for hematologic parameters (n = 4/day). Notable differences were observed in A) white blood cell (WBC), B) granulocyte, and
C) lymphocyte populations, but not D) platelet counts. Mean and standard deviations are shown. Data from 1 sham-infected control animal
per day are included for comparison.*** P< 0.001 compared to sham-infected animals.
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increasing viral burden in the blood triggers the release
of proinflammatory cytokines that drive vascular leak,
which likely contributes to the demise of the mice. In-
deed, low-level viremia begins on day 6 post infection, at
which time elevations in systemic proinflammatory me-
diators such as IL-6 and MCP-1 are detected, and likely
contribute to the increased vascular permeability which
begins on day 8, and may contribute to mortality com-
monly observed between days 10 and 12.Thus, in addition
to providing a platform for proof-of-concept studies for
early stage antiviral drug development, the TCRV AG129
mouse infection model may also be useful to evaluate
strategies under consideration for limiting vascular leak
due to sepsis [18].
Previously, we reported on the dramatic protective
effect conferred by MY-24 treatment of mice challenged
with TCRV [14]. Most impressive was the fact that ther-
apy was still effective even when delaying the initiation
of MY-24 treatment as late as 5 days post infection. Re-
markably, as confirmed in the present study, treatment
did not significantly reduce virus titers, suggesting that
the beneficial protective effect may be due to amelioration
of the pathogenesis related to an overzealous host re-
sponse. In a preliminary study investigating the potential
effect of MY-24 on vascular permeability at day 9 post-TCRV infection, there was a slight but insignificant re-
duction observed. This result, combined with limited
compound availability, has halted further investigations
into the mechanism by whichMY-24 prevents death in
AG129 mice infected with TCRV.
In regards to the immune response to TCRV in the
AG129 mice, the lack of cytokine production in kidney and
brain is consistent with the delay in appearance of virus in
those tissues. Furthermore, the subdued proinflammatory
cytokine response in kidney and brain tissues likely ac-
counts for the absence of histopathology. The more robust
cytokine responses in spleen, liver, and lung tissues were
consistent with the more prominent pathology observed in
those tissues and suggest that immunopathology plays
an important role in the process. Interestingly, the brain
was the only tissue in which viral loads increased grad-
ually out to 32 days post infection. This is striking in
that systemic virus was cleared by day 24. This suggests
that the high and constant titers found in the brains of
TCRV-challenged animals on days 24, 32, and 40 were
the results of viral replication and persistence in the
brain, and not continued seeding from circulating virus.
Arenaviruses are zoonotic agents that produce subclin-
ical infections in their respective rodent reservoir species.
An interesting and unexpected finding from our studies
was that surviving mice go on to develop chronic infection
Table 1 Cytokine response to TCRV infection
Days post-infection
Tissue Cytokine Sham-infected 3 4 5 6 7 8 9 10
Serum IL-4 9 ± 8 nd nd < 4a 26 ± 15 38 ± 7 27 ± 7 41 ± 24 44 ± 16
IL-6 103 ± 75 nd nd 95 ± 73 516 ± 450 605 ± 192 438 ± 119 1927 ± 1431 3362 ± 3163
IL-10 12 ± 7 nd nd 91 ± 22 106 ± 10 111 ± 60 172 ± 29 1110 ± 1055 598 ± 500
IL-17 10 ± 3 nd nd 28 ± 1 38 ± 19 34 ± 2 46 ± 20 129 ± 88 68 ± 27*
MCP-1 81 ± 65 nd nd 65 ± 8 733 ± 467 749 ± 129 688 ± 255 1257 ± 419** 1590 ± 665***
TNF-α 35 ± 10 nd nd < 7a 12 ± 7 57 ± 8 79 ± 32 165 ± 59 244 ± 136*
MIP-1α 52 ± 49 nd nd < 2a 24 ± 18 28 ± 22 593 ± 493 1023 ± 613 1041 ± 770
GM-CSF 30 ± 9 nd nd 91 ± 22 95 ± 24 178 ± 121 147 ± 81 350 ± 292 371 ± 173
RANTES 52 ± 17 nd nd 55 ± 13 89 ± 4 137 ± 56 172 ± 98 402 ± 129** 520 ± 193***
Brain IL-6 306 ± 216 nd nd 206 ± 8 168 ± 51 446 ± 92 150 ± 102 848 ± 725 516 ± 224
MCP-1 198 ± 76 nd nd 90 ± 34 83 ± 1 313 ± 171 211 ± 17 1703 ± 1491 2538 ± 1315
Liver IL-1α 1513 ± 430 1915 ± 575 1841 ± 591 3398 ± 667 3066 ± 390 3293 ± 1234 5436 ± 2061 13500 ± 2089** ndc
IL-1β 8415 ± 3244 4859 ± 1427 4906 ± 1664 19130 ± 4061 17366 ± 678 15160 ± 4928 16980 ± 4176 54765 ± 8595** ndc
IL-10 759 ± 239 1457 ± 627 1425 ± 542 1918 ± 329 1569 ± 4 1694 ± 428 1112 ± 387 5010 ± 1110*** ndc
IL-17 728 ± 429 871 ± 275 855 ± 344 1864 ± 383 1486 ± 135 1065 ± 373 1347 ± 681 15409 ± 4366*** ndc
MCP-1 842 ± 298 913 ± 755 955 ± 725 6879 ± 1464** 5426 ± 446* 3326 ± 916 3752 ± 1714 12370 ± 3673*** ndc
GM-CSF 2009 ± 812 2490 ± 976 2494 ± 993 4125 ± 980 3342 ± 131 2556 ± 937 3316 ± 1598 25400 ± 926*** ndc
MIP-1α 2630 ± 867 2464 ± 778 2276 ± 1102 834 ± 60 837 ± 46 3924 ± 1113 12205 ± 10866 80191 ± 17917*** ndc
Lung IL-1α 447 ± 134 nd nd 914 ± 332 518 ± 2 1020 ± 341 632 ± 90 1590 ± 1620 9510 ± 7262*
IL-2 393 ± 38 nd nd 490 ± 8 633 ± 15 1690 ± 452 2000 ± 632 3012 ± 1502 8423 ± 7650
IL-3 392 ± 101 nd nd 334 ± 36 364 ± 138 355 ± 104 279 ± 45 407 ± 126 2403 ± 101**
IL-4 401 ± 128 nd nd 493 ± 286 328 ± 242 786 ± 156 486 ± 94 868 ± 411 3914 ± 2030**
IL-5 777 ± 110 nd nd 609 ± 335 590 ± 30 1361 ± 273 891 ± 221 2033 ± 1246 5604 ± 2536***
IL-6 500 ± 216 nd nd 276 ± 345 995 ± 314 998 ± 198 1490 ± 1130 2059 ± 815 6680 ± 4214
IL-10 266 ± 24 nd nd < 6b 194 ± 235 445 ± 165 1110 ± 942 1620 ± 1511 2340 ± 1174
IL-12 613 ± 270 nd nd 129 ± 153 528 ± 568 751 ± 256 485 ± 132 704 ± 218 3348 ± 1584**
MCP-1 338 ± 74 nd nd 543 ± 38 1590 ± 245 1506 ± 148 1379 ± 355 3988 ± 3930 23780 ± 23492
TNF-α 243 ± 200 nd nd 336 ± 465 186 ± 40 705 ± 341 345 ± 93 1358 ± 1250 8622 ± 4184**
MIP-1α 565 ± 216 nd nd < 8b < 8b 1505 ± 148 1379 ± 355 3988 ± 3929 23781 ± 23492














Table 1 Cytokine response to TCRV infection (Continued)
Spleen IL-1β 5166 ± 2212 20596 ± 1045 35663 ± 16622* 16470 ± 7867 72114 ± 20013*** 71460 ± 25186*** 17603 ± 4578 17558 ± 7660 15264 ± 15228
IL-2 302 ± 60 1094 ± 377 1907 ± 871 1428 ± 745 925 ± 413 9384 ± 1767*** 2418 ± 1912 471 ± 136 668 ± 296
IL-6 937 ± 891 315 ± 206 3932 ± 1552 7512 ± 4901 8855 ± 8640 11803 ± 10907 11662 ± 7191 10277 ± 15901 7872 ± 6471
IL-10 359 ± 181 555 ± 427 2513 ± 1028 9723 ± 6700 2933 ± 3526 34446 ± 12413*** 10644 ± 11632 974 ± 475 10010 ± 3066
MCP-1 65 ± 174 1774 ± 734 3186 ± 1247 2686 ± 1874 10124 ± 2102 8822 ± 6241 10004 ± 6407 11378 ± 8843 37106 ± 34700**
MIP-1α 2460 ± 1335 3439 ± 457 10489 ± 6500 21290 ± 14825 50613 ± 23941 46596 ± 3376 79600 ± 40143 174281 ± 161060 221110 ± 206073*
a Minimum level of detection for the relevant serum cytokines: < 4 pg/ml for IL-4, < 2 pg/ml for IL-10, < 7 pg/ml for TNF-α, < 2 pg/ml for MIP-1α.
b Minimum level of detection for the relevant lung cytokines: < 6 pg/g for IL-10, < 8 pg/g for MIP-1α.
c Day 10 liver samples were compromised and therefore not included in the analysis.



























Figure 5 Evaluation of vascular permeability during TCRV infection in AG129 mice. TCRV- and sham-infected mice were infused with EBD
on day 4, 7, 8, 9 and 10 of infection and systemic levels, as well as leakage into the viscera was evaluated. A) Individual mouse weights on day 0,
2, 4, 6, 8, 9, and 10 post-infection were determined and the data are presented as the group mean and standard deviation of the percent change
in weight of surviving animals relative to their starting weights. B) Serum EBD levels and ratios of tissue to respective serum levels are shown for
C) kidney, D), liver, E) lung, and F) spleen tissues. Day 9 data include values from two separate experiments. *P< 0.05, ** P< 0.01, *** P< 0.001
compared to sham-infected animals.
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We found that the weight loss nadir in MY-24-treated
mice from days 18 to 21, prior to the recovery of the
animals, is consistent with the systemic clearance of the
virus between the 16 and 24-day time points. Importantly,
however, the AG129 mice lack type I and II IFN receptors,
and thus it is difficult to draw conclusions regarding
the biological significance of this finding. Arenaviruses
likely antagonize native rodent IFN response pathways,while eliciting a controlled cytokine response with min-
imal disruption of the endothelial barrier. Conse-
quently, one can envisage the evasion of the immune
response with limited host-mediated pathogenesis as
central mechanisms by which arenaviruses establish
chronic carrier states. Additional studies investigating
the long-term carriage of TCRV in AG129 mice may





Figure 6 Analysis of serum and tissue virus titers in AG129 mice infected with TCRV and treated with MY-24. Groups of 5–6 TCRV-infected
animals treated with MY-24 or placebo for up to 8 days starting on day 3 post-challenge were sacrificed on the specified days of infection for analysis
of A) serum, B) liver, C) lung, D) spleen, E) brain, and F) kidney virus titers. One mouse per group at days 24 and 32, and 2 mice in the 40-day group
succumbed prior to the time of sacrifice and therefore were not included in the analysis.
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Animals
Six- to seven-week-old AG129 IFN-α/β and –γreceptor-
deficient mice were used in these experiments and were
obtained from the breeding colony at Utah State University
(USU). Mice were age and gender matched for all exper-
iments. They were fed irradiated mouse chow and auto-
claved water ad libitum. All animal procedures were
conducted at the AAALAC-accredited Laboratory Animal
Research Center at USU, were approved by the USU Insti-
tutional Animal Care and Use Committee (IACUC), and
complied with USDA guidelines.
Virus
TCRV, strain TRVL 11573, was obtained from American
Type Culture Collection (ATCC; Manassas, VA). The virus
stock (106.35 CCID50/ml) used was prepared from clarified
liver homogenates from AG129 mice challenged with
TCRV (2 passages in Vero 76 African green monkey kidneycells). Virus stock was diluted in sterile minimal essential
medium (MEM) supplemented with 50 μg/ml gentamicin
and inoculated by intraperitoneal (i.p.) injection.
Characterization of the AG129 mouse response to
TCRV infection
Mice were challenged with approximately 500 CCID50 of
TCRV and groups of 4 animals were sacrificed daily. Ten
sham-infected mice (normal controls) were included in
the study for daily sacrifice (one per day) and comparison
to the TCRV-challenged animals. Serum and liver, spleen,
brain, kidney, and lung tissues were obtained for virus
titer determination and cytokine profiling. The spleen
from all animals was weighed prior to processing for
virus titer. Whole blood collected in EDTA-coated tubes
was analyzed for hematology using the VetScan HMT
(Abaxis Inc. Union City, CA). A sample of each tissue
was preserved in 10% formalin and sent to the Ross A.
Smart Veterinary Diagnostic Laboratory (VDL; Logan,
Figure 7 Analysis of weight change in AG129 mice infected
with TCRV and treated with MY-24 or placebo. Mice from the
longitudinal study described in Figure 6 were weighed every third
day over the course of the experiment. Normal control mice (n=5,
with 1 mouse each sacrificed on days 8, 16, 24, 32, and 40) are included
for comparison. The data are represented as the group mean and
standard deviation of the percent change in weight of surviving animals
relative to their starting weights. Because placebo-treated animals were
sacrificed on day 8, only weights through day 6 were determined.
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tissue homogenates in MEM and serum were stored
at −80°C until time of analysis.
Tissue virus titer determinations
Virus titers were assayed using an infectious cell culture
assay as previously described [19]. Briefly, a specific volume
of tissue homogenate or serum was serially diluted and
added to triplicate wells of Vero 76 cell monolayers inFigure 8 Neutralizing antibody levels during the course of TCRV
infection and recovery in AG129 mice treated with MY-24. Serum
samples from TCRV-infected animals treated with MY-24 or placebo, as
indicated in the longitudinal study described in Figure 6, were
analyzed for neutralizing antibodies by PRNT. Normal serum from
uninfected mice and immune serum were included as controls.96-well microtiter plates. The viral cytopathic effect (CPE)
was determined 7–8 days post-virus inoculation, and the
titers were calculated by endpoint titration [20]. The assay
limits of detection were 2.8 log10 CCID50/g of tissue or 1.8
log10 CCID50/ml of serum.
Multiplex cytokine profiling
Tissue and serum concentrations of 16 cytokines(IL-1α,
IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12, IL-17,
MCP-1, IFN-γ, TNF-α, MIP-1α, GM-CSF, and RANTES)
were evaluated in TCRV-infected mice using Q-Plex mouse
cytokine arrays (BioLegend, San Diego, CA) as recom-
mended by the manufacturer. Samples collected on days 2-
10 post-infection with TCRV were analyzed for serum and
tissue concentrations of the indicated cytokines using the
multiplexed array. Samples from normal control animals
(n=3-6) were included to establish baseline cytokine concen-
trations in AG129 mice. The data are presented as pg/ml of
serum or pg/g of tissue.
Assessment of vascular leakage
In a separate time course experiment, vascular perme-
ability was determined by tracking EBD diffusion into
various tissues as previously described in a study meas-
uring vascular leak in Pichinde virus and yellow fever
virus hamster models of viral HF [16]. Briefly, mice chal-
lenged with TCRV were anesthetized at indicated times
post-infection with isoflurane and injected retro-orbitally
with a 0.5% EBD (Sigma-Aldrich, St. Louis, MO)
in phosphate-buffered saline (PBS). Three h after EBD in-
fusion, blood was collected by cheek bleed prior to exten-
sive transcardial perfusion with PBS. Sections of liver,
spleen, lung, and kidney tissues were harvested and the
dye extracted by overnight incubation in formamide at
37°C. Relative EBD content in the serum was deter-
mined from 1:10 diluted samples measured at 610 nm
and 740 nm. The absorbance at 740 nm was subtracted
from the 610 nm absorbance values to remove contributions
due to hemoglobin contamination. Data were expressed as
the ratio of absorbance/g of tissue:absorbance of a 10-fold
dilution of the respective serum sample.
Recovery of TCRV-infected mice treated with MY-24
Groups of mice (n=5-6/group) mice were treated i.p. with
saline vehicle placebo or 25 mg/kg of MY-24, once daily
for up to 8 days starting 3 days post-challenge with 500
CCID50 of TCRV. A group of MY-24- and placebo-treated
mice were sacrificed on day 8, and the remaining 4-5mice
per MY-24 group were sacrificed on days 16, 24, 32 and
40 relative to time of infection. Placebo-treated animals
were not included for these later time points because they
would not be expected to survive the TCRV challenge.
Five sham-infected normal control mice were included in
the study for sacrifice at the different time points and
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liver, spleen, brain, kidney, and lung tissues were collected
for viral titer analysis. Due to death prior to time of sacri-
fice, 1 of 5 animals in the 24- and 32-day groups, and 2
of 6 animals in the 40-day group were not included in
the analysis.
In a separate experiment using the same challenge dose
and treatment regimen, we also determined the effect of
MY-24 on vascular permeability on day 9 post-infection.
EBD content in the serum and tissues was measured as
described above and compared to mice that were treated
with placebo, or sham-infected controls.
Serum plaque reduction and neutralization titers (PRNT)
Neutralizing antibody titers were determined by standard
PRNT assay. Briefly, equal volumes of media containing
400 CCID50 of TCRV were added to serial 2-fold dilutions
of heat-inactivated (56°C for 30 min) serum samples di-
luted in MEM supplemented with 2% FBS and incubated
at 37°C prior to adding the mixtures to 6-well plates
seeded with Vero 76 cells. After a 2-h absorption period,
the cells were washed with PBS and a 1% sea plaque agar-
ose (Lonza, Rockland, ME) MEM/2% FBS/gentamicin over-
lay added. Following a day-6 culture period, the cells were
stained with neutral red solution and plaques visualized
with the aid of a light box. The neutralizing antibody titers
were expressed as the highest dilution of serum reducing
the average number of plaques present in the virus control
wells (TCRV incubated with normal serum) by 50% or
greater (PRNT50).
Statistical analysis
For analyzing differences in spleen weights, cytokine levels,
hematology parameters, PRNT and vascular permeability,
one-way analysis of variance with Newman-Keuls post-
tests were performed. Day 8 serum and tissue virus titer
comparisons between MY-24 and placebo treatments were
made using the Mann–Whitney test. All statistical evalua-
tions were done using Prism (GraphPad Software, CA).
Additional file
Additional file 1: Figure S1. Evaluation of vascular permeability in
TCRV-infected mice treated with MY-24. TCRV-infected mice treated with
MY-24 or placebo, starting 3 days after challenge, were infused with EBD
on day 9 of infection and systemic levels, as well as leakage into the
viscera, were evaluated. A) Serum EBD levels and ratios of tissue to
respective serum levels are shown for B), kidney C) liver, and D) spleen
tissue. *P< 0.05, ** P< 0.01, *** P< 0.001 compared to sham-infected
normal animals.
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